PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Status:
Recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
Concurrent chemoradiotherapy is now considered to be the standard treatment modality for
esophageal cancer patients who are medically unfit for surgery. However, elderly patients
have limitations in their ability to tolerate concurrent chemoradiotherapy in comparison to
nonelderly patients because of medical comorbidities and reduced functional reserve of
organs. Immune checkpoint inhibitors, including PD-1 inhibitor, have been used in a large
number of clinical studies on esophageal cancer and have achieved certain results. PD-1
inhibitor combined with radiotherapy may be a new strategy for elderly patients with
esophageal cancer. This study aims to explore the efficacy and safety of PD-1 inhibitor
combined with radiotherapy in the treatment of elderly patients with esophageal cancer. PD-1
inhibitor was delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after
radiotherapy for one year.